SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving FDA Fast Track designation for sonelokimab in palmoplantar pustulosis, a development the community views as a major de-risking catalyst. Despite this positive news, many are actively discussing perceived market manipulation, believing the stock is undervalued and anticipating significant updates on clinical data and strategic direction at the upcoming Investor Day.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space is trending as its IPO quiet period concludes and investors await potential news regarding an FAA Space Launch license, fueling community debate over its tiny float and high short interest, particularly amidst broader speculation for the upcoming Space X IPO.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is actively discussed after its recent earnings report, coupled with strategic acquisitions and a major AI security partnership with Google Cloud, as the community expresses mixed views on the cybersecurity leader's aggressive expansion and valuation in the evolving AI threat landscape.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as recent weak performance and a cautious outlook for 2026 have pushed the stock to multi-year lows, fueling intense debate. While many investors fear a downturn due to declining U.S. sales and an ongoing CEO search, others argue the iconic brand is undervalued with a strong dividend, believing all negativity is already factored into the price, amplified by significant put option activity.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is surging to new highs following strong Q2 earnings, raised guidance, and bullish analyst upgrades, fueled by its pivotal role in AI data center optical infrastructure. While many celebrate its breakout momentum, others caution about extreme overvaluation, insider selling, and the stock's parabolic run as a 'meme pump' ripe for a significant correction.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as its AXPAXLI drug met the primary superiority endpoint in a Phase 3 wet AMD trial, but a surprising sell-off has ignited a community debate on whether the market overreacted to the control arm's performance, fueling speculation of a strategic buying opportunity and potential acquisition.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion Inc. ($INFQ) is seeing significant attention as it begins trading after its SPAC merger, positioning itself as a leader in neutral-atom quantum technology. The community is highly optimistic, emphasizing its undervalued status compared to competitors, major partnerships with entities like NVIDIA and NASA, and real-world defense contracts driving long-term growth potential.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending after Hapag-Lloyd confirmed an agreement to acquire the shipping company for $35 per share in an all-cash deal. The community is actively discussing the arbitrage opportunity, the stock's trading discount to the buyout price, and perceived risks related to regulatory approvals, geopolitical factors, and potential dividends before the expected late 2026 deal close.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending due to recent earnings call comments from its CEO, fueling speculation that its Mears Silicon Technology (MST) is making significant progress with major chipmakers for Gate-All-Around and DRAM, alongside breakthroughs in GaN-on-Silicon for AI and data centers. The community is actively debating whether record trading volumes and increased management accountability signal a long-awaited valuation reset for the pre-revenue semiconductor innovator.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending following strong Phase 3 trial results for its COMP360 psilocybin therapy in treatment-resistant depression, with the community buzzing about its statistically significant efficacy, rapid onset, and the company's accelerated path towards potential FDA approval and commercial launch as a pioneering psychedelic treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

🚨 $MTVA : AI Analysis Strengthens The Case For Vanoglipel 
 
MetaVia is a Clinical stage biotech targeting cardiometabolic diseases such as obesity, fatty liver and diabetes. 
 
Today’s News! 
 
MetaVia reported new results from its AI collaboration with Syntekabio using the DeepMatcher platform. 
 
The AI modeled compound-protein interactions for vanoglipel and identified where the drug is biologically active. 
 
What the modeling showed: 
 
➡️ Strong engagement of inflammatory pathways 
➡️Alignment with cardiometabolic disease biology 
➡️Supports development in MASH and Type 2 diabetes 
➡️Cancer pathways also appeared due to inflammation reduction mechanisms 
 
It also matches earlier Phase 2a findings: 
➡️Direct liver activity 
➡️Improved glucose metabolism 
 
The AI data reinforces that vanoglipel’s biology makes sense and lowers scientific risk as development moves forward, especially for MASH and diabetes. 
 
Communicated Disclaimer: https://chartingdaily.com/metabolic-health 
 
Sector Peers: $GPCR $ALT $TERN $REGN

JCOOP

NASDAQ: MTVA A Concentrated Approach to Cardiometabolic Therapeutic Innovation MetaVia (NASDAQ: MTVA) offers investors a targeted opportunity to gain exposure to the advancing cardiometabolic therapeutic landscape addressing large and growing global health challenges.

Stock Research Today -

The Evolving Landscape of Metabolic and Cardiometabolic Disease - Stock Research Today

StockTwits Web

MetaVia Inc.

Structure Therapeutics Inc - ADR

Altimmune Inc

Terns Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc.

 : AI Analysis Strengthens The Case For Vanoglipel 
 
MetaVia is a Clinical stage biotech targeting cardiometabolic diseases such as obesity, fatty liver and diabetes. 
 
Today’s News! 
 
MetaVia reported new results from its AI collaboration with Syntekabio using the DeepMatcher platform. 
 
The AI modeled compound-protein interactions for vanoglipel and identified where the drug is biologically active. 
 
What the modeling showed: 
 
➡️ Strong engagement of inflammatory pathways 
➡️Alignment with cardiometabolic disease biology 
➡️Supports development in MASH and Type 2 diabetes 
➡️Cancer pathways also appeared due to inflammation reduction mechanisms 
 
It also matches earlier Phase 2a findings: 
➡️Direct liver activity 
➡️Improved glucose metabolism 
 
The AI data reinforces that vanoglipel’s biology makes sense and lowers scientific risk as development moves forward, especially for MASH and diabetes. 
 
Communicated Disclaimer: 